Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

In our Part 1 breakdown of Verdad Capital's 2026 white paper, we covered the core finding: specialist fund ownership is the strongest quality signal in biotech, with a 22-percentage-point annualized return spread from bottom to top quintile. Insider trades and short interest add further predictive power. But the paper goes deeper. Verdad asks: can you build a full quantitative model for biotech — with value, momentum, and quality factors — the way you would for any other sector? The answer is yes, but you have to throw out the standard definitions and rebuild them from scratch.

In most industries, cheap stocks outperform expensive stocks. In biotech, the opposite is true. When Verdad applies the standard value factor — profits relative to enterprise value — the cheapest quintile actually underperforms the most expensive. The reason is straightforward: 69% of biotech companies have zero revenue. "Cheap" on a profit basis in biotech usually means the market has given up on the company, not that it's undervalued. Verdad's fix: replace profits with spending as the value anchor. Clinical trials are expensive and not undertaken lightly — a company's total R&D spend is a better proxy for the value of its pipeline than its (nonexistent) profits. With this modified metric, value works again: the cheapest quintile on the spending-based metric returned 19% annualized vs. -6% for the most expensive.

Standard momentum — buying stocks with strong trailing returns — is one of the most durable factors in finance. In biotech, it's inverted. The worst-performing stocks have the best forward returns, and the best-performing stocks have the lowest. This is likely because biotech stocks mean-revert after binary catalyst events. Verdad's solution uses their clinical trial database of 130,000+ trials. They built a peer-similarity model that groups companies by the attributes of their clinical programs — disease area, clinical stage, therapeutic modality. Then they measure momentum not by the stock's own trailing returns, but by the returns of its closest scientific peers. This "peer momentum" works: the top quintile returned 12% annualized vs. -1% for the bottom. The insight is that when companies pursuing similar science are doing well, there's a therapeutic tailwind that benefits the whole cluster — think GLP-1 agonists lifting all obesity-focused biotechs, or ADC momentum spreading across the antibody-drug conjugate space.

When Verdad combines all three biotech-specific factors — specialist quality, modified value, and peer momentum — into a single blended model, the return spread is dramatic: - Quintile 1 (worst composite score): -17% annualized - Quintile 5 (best composite score): 21% annualized That's a 38-percentage-point spread. The blended model outperforms any single factor, and crucially, it identifies not just longs but shorts — companies that are expensive, disliked by specialists, and in declining therapeutic areas. Verdad's backtest of a long-short portfolio using this model (January 2015 to August 2025, net of all trading and borrowing costs) returned 19.1% annualized with 18.9% volatility — a Sharpe ratio of 1.01. For comparison, XBI returned 3.7% with 33.2% volatility over the same period, and the S&P 500 returned 13.3%. The max drawdown was -32% vs. -64% for XBI.

Verdad closes with a macro argument. Since December 2019, the S&P Biotech Index returned just 4.5% annually vs. 15.1% for the S&P 500 — still down 21% from its February 2021 peak. But historically, comparable drawdowns have been followed by 60%+ returns over the subsequent two years. Three tailwinds they cite: an estimated $200 billion in annual drug revenues at risk by 2030 from patent expirations (forcing pharma to acquire), a record pace of FDA approvals (50 in 2024, 46 in 2025, with 72% developed by small/mid companies), and AI-driven R&D improvements that could cut development timelines by 6-12 months. As Stifel's Tim Opler put it: "The generalists are gone from our market." Verdad sees this consensus pessimism as exactly the condition where disciplined, data-driven biotech investing pays off most.

You don't need to run a long-short quant fund to benefit from Verdad's findings. The core takeaways are actionable for any biotech investor: 1. Follow the specialists. The 22-point return spread by specialist concentration is the single strongest signal. Track what the dedicated biotech funds are buying. 2. Filter insider noise. Not all Form 4 filings are equal — focus on discretionary buys, reversals, and cluster purchases, not routine option exercises. 3. Ignore traditional valuation metrics. Price-to-earnings and book value are meaningless for pre-revenue biotechs. Cash runway and R&D spending are better anchors. 4. Watch therapeutic momentum. When a drug class is working (GLP-1s, ADCs, radioligand therapies), the whole cluster tends to benefit. BiotechEdge implements all four of these principles — specialist fund tracking, insider noise filtering, cash runway analysis, and catalyst mapping — in a single daily-updated platform. The Verdad paper provides the evidence. We provide the implementation.